Suppr超能文献

多种微管改变与人类白血病细胞对长春花生物碱的耐药性相关。

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

作者信息

Kavallaris M, Tait A S, Walsh B J, He L, Horwitz S B, Norris M D, Haber M

机构信息

Children's Cancer Institute Australia for Medical Research, High Street, Randwick, NSW, Australia 2031.

出版信息

Cancer Res. 2001 Aug 1;61(15):5803-9.

Abstract

Vinca alkaloids are used extensively in the treatment of childhood acute lymphoblastic leukemia (ALL) and despite their usefulness, drug resistance remains a serious clinical problem. Vinca alkaloids bind to the beta-tubulin subunit of the alpha/beta-tubulin heterodimer and inhibit polymerization of microtubules. Recent studies have implicated altered beta-tubulin isotype expression and mutations in resistance to microtubule-stabilizing agents. Microtubule-associated protein (MAP) MAP4 binds to and stabilizes microtubules, and increased expression is associated with decreased sensitivity to microtubule-depolymerizing agents. To address the significance of beta-tubulin and MAP4 alterations in childhood ALL, two CCRF-CEM-derived Vinca alkaloid resistant cell lines, VCR R (vincristine) and VLB100 (vinblastine), were examined. Decreased expression of class III beta-tubulin was detected in both VCR R and VLB100 cells. VCR R cells and to a lesser extent VLB100 cells expressed increased levels of MAP4 protein. Increased microtubule stability was observed in these VCR R cells as identified by the high levels of polymerized tubulin (45.6 +/- 2.6%; P < 0.005) compared with CEM and VLB100 cells (24.7 +/- 3.3% and 24.7 +/- 2.5%, respectively). Expression was associated with a single MAP4 isoform in the polymerized microtubule fraction in CEM and VCR cells. In contrast, VLB100 cells expressed a lower molecular weight isoform in the polymerized fraction. Two-dimensional-PAGE and immunoblotting revealed marked posttranslational changes in class I beta-tubulin in VCR R cells not evident in CEM cells. Sequencing of the beta-tubulin (HM40) gene identified a point mutation in VCR R cells in nucleotide 843 (CTC-->ATC; Leu(240)-->Ile) that was not present in CEM or VLB100 cells. This mutation resides in a region of beta-tubulin that lies in close proximity to the alpha/beta tubulin interface. Multiple alterations related to normal microtubule function were identified in ALL cells selected for resistance to Vinca alkaloids, and these alterations may provide important insight into mechanisms mediating resistance to Vinca alkaloids.

摘要

长春花生物碱被广泛用于治疗儿童急性淋巴细胞白血病(ALL),尽管其疗效显著,但耐药性仍是一个严重的临床问题。长春花生物碱与α/β-微管蛋白异二聚体的β-微管蛋白亚基结合,抑制微管聚合。最近的研究表明,β-微管蛋白亚型表达改变和对微管稳定剂的耐药性中的突变有关。微管相关蛋白(MAP)MAP4与微管结合并使其稳定,其表达增加与对微管解聚剂的敏感性降低有关。为了探讨β-微管蛋白和MAP4改变在儿童ALL中的意义,研究人员检测了两种源自CCRF-CEM的长春花生物碱耐药细胞系,VCR R(长春新碱)和VLB100(长春碱)。在VCR R和VLB100细胞中均检测到III类β-微管蛋白表达降低。VCR R细胞以及程度较轻的VLB100细胞中MAP4蛋白水平升高。与CEM和VLB100细胞(分别为24.7±3.3%和24.7±2.5%)相比,这些VCR R细胞中观察到微管稳定性增加,这通过高水平的聚合微管蛋白得以证实(45.6±2.6%;P<0.005)。在CEM和VCR细胞的聚合微管部分中,表达与单一MAP4亚型相关。相比之下,VLB100细胞在聚合部分中表达较低分子量的亚型。二维聚丙烯酰胺凝胶电泳和免疫印迹显示,VCR R细胞中I类β-微管蛋白存在明显的翻译后变化,而在CEM细胞中不明显。β-微管蛋白(HM40)基因测序在VCR R细胞中鉴定出核苷酸843处的一个点突变(CTC→ATC;Leu(240)→Ile),该突变在CEM或VLB100细胞中不存在。该突变位于β-微管蛋白中靠近α/β微管蛋白界面的区域。在选择对长春花生物碱耐药的ALL细胞中鉴定出了与正常微管功能相关的多种改变,这些改变可能为介导对长春花生物碱耐药的机制提供重要见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验